title: CRH functions as a growth factor/cytokine in the skin.
abstract: We tested the effect of CRH and related peptides in a large panel of human skin cells for growth factor/cytokine activities. In skin cells CRH action is mediated by CRH-R1, a subject to posttranslational modification with expression of alternatively spliced isoforms. Activation of CRH-R1 induced generation of both cAMP and IP3 in the majority of epidermal and dermal cells (except for normal keratinocytes and one melanoma line), indicating cell type-dependent coupling to signal transduction pathways. Phenotypic effects on cell proliferation were however dependent on both cell type and nutrition conditions. Specifically, CRH stimulated dermal fibroblasts proliferation, by increasing transition from G1/0 to the S phase, while in keratinocytes CRH inhibited cell proliferation. In normal and immortalized melanocytes CRH effect showed dichotomy and thus, it inhibited melanocyte proliferation in serum-containing medium CRH through G2 arrest, while serum free media led instead to CRH enhanced DNA synthesis (through increased transition from G1/G0 to S phase and decreased subG1 signal, indicating DNA degradation). CRH also induced inhibition of early and late apoptosis in the same cells, demonstrated by analysis with the annexin V stains. Thus, CRH acts on epidermal melanocytes as a survival factor under the stress of starvation (anti-apoptotic) as well as inhibitor of growth factors induced cell proliferation. In conclusion, CRH and related peptides can couple CRH-R1 to any of diverse signal transduction pathways; they also regulate cell viability and proliferation in cell type and growth condition-dependent manners.
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA. aslominski@utmem.edu
authors.forename: A
authors.initials: A
authors.lastname: Slominski
authors.forename: B
authors.initials: B
authors.lastname: Zbytek
authors.forename: A
authors.initials: A
authors.lastname: Pisarchik
authors.forename: R M
authors.initials: RM
authors.lastname: Slominski
authors.forename: M A
authors.initials: MA
authors.lastname: Zmijewski
authors.forename: J
authors.initials: J
authors.lastname: Wortsman
mesh_terms: D017209:Apoptosis; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism / Q000502:physiology*; D016207:Cytokines / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D015603:Keratinocytes; D008545:Melanoma / Q000503:physiopathology*; D018019:Receptors, Corticotropin-Releasing Hormone / Q000502:physiology*; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism*; D015398:Signal Transduction; D012867:Skin / Q000166:cytology / Q000378:metabolism* / Q000473:pathology; D012878:Skin Neoplasms / Q000378:metabolism; D000099052:CRF Receptor, Type 1
chemical_list: D016207:Cytokines; D006133:Growth Substances; D018019:Receptors, Corticotropin-Releasing Hormone; D043562:Receptors, G-Protein-Coupled; D000099052:CRF Receptor, Type 1; D003346:Corticotropin-Releasing Hormone